Lexaria Bioscience Corp. (LEXX)

Lexaria Bioscience Balance Sheet

Financials in millions USD. Fiscal year is September - August.

Assets

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	May 31, 2026	Aug 31, 2025	Aug 31, 2024	Aug 31, 2023	Aug 31, 2022	Aug 31, 2021
Cash & Equivalents	3.48	1.8	6.5	1.35	5.81	10.92
Short-Term Investments	0.14	0.17	0.06	0.13	0.35	0.83
Cash & Short-Term Investments	3.62	1.97	6.56	1.48	6.16	11.75
Cash Growth	-21.80%	-69.99%	343.63%	-76.01%	-47.58%	794.97%
Accounts Receivable	-	0.17	0.08	0.02	0.12	0.02
Other Receivables	0.05	0.19	0.07	0.1	0.08	0.33
Receivables	0.05	0.37	0.15	0.13	0.2	0.34
Inventory	-	-	-	-	0.04	0.03
Prepaid Expenses	0.4	1.13	1.19	0.55	0.58	0.32
Total Current Assets	4.06	3.47	7.9	2.15	6.98	12.44
Property, Plant & Equipment	0.31	0.33	0.39	0.42	0.37	0.46
Other Intangible Assets	0.34	0.31	0.52	0.46	0.49	0.36
Other Long-Term Assets	0.06	0.06	0.06	0.05	-	-
Total Assets	4.78	4.18	8.87	3.08	7.83	13.27

Liabilities

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	May 31, 2026	Aug 31, 2025	Aug 31, 2024	Aug 31, 2023	Aug 31, 2022	Aug 31, 2021
Accounts Payable	0.1	0.57	0.38	0.23	0.12	0.06
Accrued Expenses	0.25	0.89	0.69	0.01	0.03	0.05
Short-Term Debt	-	-	-	-	-	0.01
Current Portion of Leases	0.03	0.03	0.03	0.03	0.04	0.04
Current Income Taxes Payable	-	-	-	-	-	0
Current Unearned Revenue	-	-	0	-	-	-
Total Current Liabilities	0.38	1.49	1.1	0.27	0.19	0.15
Long-Term Leases	0.05	0.08	0.11	0.14	0.01	0.05
Total Liabilities	0.44	1.57	1.21	0.4	0.2	0.2

Shareholders' Equity

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	May 31, 2026	Aug 31, 2025	Aug 31, 2024	Aug 31, 2023	Aug 31, 2022	Aug 31, 2021
Common Stock	0.02	0.02	0.02	0.01	0.01	0.01
Additional Paid-In Capital	73.26	66.5	59.6	48.8	47.04	45.09
Retained Earnings	-68.5	-63.46	-51.56	-45.76	-39.1	-31.83
Comprehensive Income & Other	-0.05	-0.07	-0.02	-	-	-
Total Common Equity	4.74	2.99	8.04	3.04	7.95	13.27
Minority Interest	-0.39	-0.39	-0.38	-0.36	-0.32	-0.2
Shareholders' Equity	4.34	2.6	7.66	2.68	7.63	13.06
Total Liabilities & Equity	4.78	4.18	8.87	3.08	7.83	13.27

Additional Metrics

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	May 31, 2026	Aug 31, 2025	Aug 31, 2024	Aug 31, 2023	Aug 31, 2022	Aug 31, 2021
Total Debt	0.09	0.11	0.14	0.16	0.05	0.1
Net Cash (Debt)	3.53	1.86	6.42	1.31	6.11	11.65
Net Cash Growth	-21.70%	-71.05%	388.54%	-78.50%	-47.57%	907.32%
Net Cash Per Share	2.35	1.55	7.77	2.98	15.57	39.81
Filing Date Shares Outstanding	1.65	1.48	1.16	0.69	0.4	0.38
Total Common Shares Outstanding	1.65	1.3	1.05	0.54	0.4	0.38
Working Capital	3.68	1.97	6.8	1.88	6.78	12.29
Book Value Per Share	2.87	2.29	7.62	5.64	20.04	34.75
Tangible Book Value	4.4	2.68	7.52	2.58	7.46	12.9
Tangible Book Value Per Share	2.66	2.06	7.13	4.79	18.80	33.79
Machinery	0.58	0.54	0.51	0.47	0.44	0.39
Leasehold Improvements	0.26	0.26	0.26	0.26	0.26	0.26

SEC Filings: 10-K · 10-Q

Data Source: S&P Global Market Intelligence Last updated: Apr 13, 2026

Financial data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Aug 24, 2026

Data Sources Report a data error